血液透析联合血液灌流治疗中抗凝剂的合理运用

摘要

Objective This study describes the use of anticoagulants in 23 cases of chronic maintenance hemodialysis. Methods Patients were randomLy divided into a control group and an experimental group. Included ACT monitoring using heparin anticoagulation, observing the patient’s blood coagulation, and individual heparin dosage. Results Include a difference in ACT under the monitoring of anticoagulant dose and time factors, affecting the hemoperfusion target value. Conclusion The use of anticoagulants require hemodialysis ACT target value of 170-250s safe range for the empirical. Hemoperfusion in this experiment demonstrated the range of 300-350s safe blood was not caused by bleeding. As between individuals, the same batch of heparin perfusion why there are different consumption differences in the speciifc surface area and pore volume are related remains to be further explored.%　　目的 准确掌握抗凝剂的使用量。方法 23例慢性维持性血液透析患者入选本研究，随机分为对照组和实验组，在ACT监测下使用肝素抗凝，观察患者出凝血情况，及个体肝素使用剂量。结果 ACT监测下抗凝剂量差异大，抗凝时间目标值得到新的定位。结论 血液透析抗凝剂的运用需ACT目标值达170~250s为经验性的安全范围。血液灌流在本实验中证实安全范围在300~350s不凝血也不引起出血。至于个体之间同批次灌流器为何肝素消耗量有不同差异，是否与比表面积孔容相关还有待进一步探讨。